Dan Zhang

Dan Zhang

Auto-generated profile, based on publicly available information

Dan Zhang

School of Pharmacy, Shaanxi University of Chinese Medicine, Xi’an, 712046, People’s Republic of China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
QFQiang-Qiang Fan
Qiang-Qiang Fan
BZBing-Tao Zhai
Bing-Tao Zhai
DZDan Zhang
Dan Zhang
XZXiao-Fei Zhang
Xiao-Fei Zhang
JCJiang-Xue Cheng
Jiang-Xue Cheng
HTHuan Tian
Huan Tian
Purpose: Yinhua Gout Granules (YGG) is a traditional Chinese medicine preparation with a variety of pharmacological effects, and its clinical efficacy in the treatment of gouty arthritis (GA) has been fully confirmed. However, the pharmacodynamic basis of YGG and its anti-inflammatory mechanism of action in GA are unknown. The objective of this study was to identify the active components and molecular mechanisms of YGG in the treatment of GA. Methods: Ultra-performance liquid chromatography-electrospray ionization tandem mass spectrometry (UPLC-ESI-MS/MS) and network pharmacology were used to identify and predict the potential active ingredients and related signaling pathways. Then, we revealed the anti-GA effects of YGG based on pharmacodynamic experiments in GA rats. Finally, we integrated transcriptomics and network pharmacology to elucidate the potential mechanism of action and verified the putative mechanism by molecular docking, immunohistochemical (IHC) and Western blot. Results: We have identified 10 major active components of YGG that may have anti-GA effects, such as ferulic acid, rutin, luteolin, etc. Using molecular docking, we found that 10 major compounds could bind well to TNF, PTGS2, IL-6, IL1β, NOS2 and PTGS1, and the binding energies were all less than − 5 kcal/mol. Animal studies have shown that YGG can improve joint inflammation and inflammatory cell infiltration, reduce serum UA, BUN and Cr levels (p< 0.01), and decrease IL-1β, IL-6, TNF-α, COX-2 and PGE2 levels in synovial tissue (p< 0.01), which are associated with the pathogenesis of GA. IHC and Western blot results showed that YGG could regulate TLR4/MYD88/NF-κB pathway to inhibit the inflammatory response induced by GA. Conclusion: This study found that YGG could not only improve the disease of GA by inhibiting the production of UA in the body, but also target the regulation of TLR4/MYD88/NF-κB signaling pathway through a variety of active components to achieve effective therapeutic effects on GA.

1 July 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
DZDan Zhang
Dan Zhang
BZBingtao Zhai
Bingtao Zhai
JSJing Sun
Jing Sun
JCJiangxue Cheng
Jiangxue Cheng
XZXiaofei Zhang
Xiaofei Zhang
DGDongyan Guo
Dongyan Guo
Dried toad skin (TS) and toad venom (TV) are the dried skin of the Bufo bufo gargarizans Cantor and the Bufo melanostictus Schneider, which remove the internal organs and the white secretions of the skin and retroauricular glands. Since 2005, cinobufacini preparations have been approved by the State Food and Drug Administration for use as adjuvant therapies in the treatment of various advanced cancers. Meanwhile, bufalenolides has been identified as the main component of TS/TV, exhibiting antitumor activity, inducing apoptosis of cancer cells and inhibiting cancer cell proliferation or metastasis through a variety of signaling pathways. However, clinical agents frequently face limitations such as inherent toxicity at high concentrations and insufficient tumor targeting. Additionally, the development and utilization of these active ingredients are hindered by poor water solubility, low bioavailability, and rapid clearance from the bloodstream. To address these challenges, the design of a targeted drug delivery system (TDDS) aims to enhance drug bioavailability, improve targeting within the body, increase drug efficacy, and reduce adverse reactions. This article reviews the TDDS for TS/TV, and their active components, including passive, active, and stimuli-responsive TDDS, to provide a reference for advancing their clinical development and use.

1 December 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
RZRong Zhang
Rong Zhang
BZBing-Tao Zhai
Bing-Tao Zhai
JQJia-Xin Qiao
Jia-Xin Qiao
DZDan Zhang
Dan Zhang
AWAi-Jia Wang
Ai-Jia Wang
DGDongyan Guo
Dongyan Guo
Breast cancer (BC) is the most common malignant tumor in women. Docetaxel (DTX), a chemotherapeutic agent derived from paclitaxel (PTX), has received approval from the US Food and Drug Administration (FDA) for the treatment of BC and various other malignancies. Nevertheless, its utility in clinical settings is constrained due to its poor water solubility and low oral bioavailability, dose-dependent toxicity, and a short systemic circulation half-life. Developing nano-drug delivery systems for DTX represents a well-established strategy to overcome these limitations. This review, based on a literature search of the PubMed database from 2019 to 2024 using the keywords “docetaxel”, “breast cancer”, and “nano-drug delivery system”, summarises recent advances in targeted nanomedicine delivery systems for DTX and their application in BC treatment when combined with other delivery therapies. Nano-drug delivery systems encompass passive targeting (such as: nanomicelles, liposomes), active targeting (such as: G protein-coupled oestrogen receptor, integrin protein receptor), physicochemical targeting (such as: magnetic-responsive, temperature-responsive), and combined delivery (such as: photothermal therapy, chemotherapeutic drugs, and active components of traditional Chinese medicine). These systems hold great promise for enhancing DTX bioavailability, improving tumor targeting, and regulating drug release. Furthermore, key challenges limiting clinical translation are analysed. This paper provides a theoretical foundation and practical guidance for rationally designing DTX nanomedicines, accelerating their transition from laboratory research to clinical application and offering new hope for BC treatment.